Total synthesis of alpha-, beta- and gamma-naphthocyclinone
α-、β-和γ-萘环酮的全合成
基本信息
- 批准号:290521118
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:德国
- 项目类别:Research Fellowships
- 财政年份:2015
- 资助国家:德国
- 起止时间:2014-12-31 至 2017-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The aim of this research project is the first total synthesis of alpha-, beta- and gamma-naphthocyclinone, three natural products from the naphthocyclinone family. All three compounds were isolated in 1974 as the colorful pigments from the mycelium of streptomyces arenae and are strong antibiotics against gram-positive bacteria. The biosynthetic pathway of naphthocyclinones was intensively investigated and it was thereby discovered that mother nature uses the monomeric pyranonaphthoquinone unit for dimerization in order to construct the naphthocyclinones.The retrosynthetic analysis envisions one common intermediate, which bears the complete carbon skeleton with its bicyclic core structure. This bicyclic core structure can be constructed via an aldol-addition by reductive cyclization, a method that was developed in the group of Suzuki. The precursor for the cyclisation could be furnished by an asymmetric rhodium-catalyzed C-C-cross coupling reaction of a western and an eastern fragment. Inspired by the biosynthesis of the naphthocyclinones, both fragments could be synthesized from one key intermediate that is a pyranonaphthalene compound.In view of the synthetic strategy, the naphthalene core of the key intermediate should be accessible by annulation of a benzoic acid ester derivative and a literature know chiral dihydropyron building block, which bears on of the stereogenic centers of the key intermediate. The pyrane ring of the key intermediate could be fully functionalized by a diastereoselective alkylation reaction of a lactol. After modulation of the key intermediate into the western and eastern fragment, the common intermediate, bearing the full carbon skeleton, could be synthesized by a cross coupling reaction and a reductive cyclisation. Following a sequence of a) oxidation to a para-naphthoquinone moiety, b) generation of a carboxylic acid functionality and c) removal of all phenol protecting groups should furnish the target compound beta-naphthocyclinone. Reversing the order of the first two steps of this sequence (first generation of the carboxylic acid functionality and then oxidation to a para-naphthoquinone moiety) should allow for a literature known lactonisation. Again removal of all phenol protecting groups should lead to gamma-naphthocyclinone. In analogy to the biosynthesis, an epoxidation followed by photochemical rearrangement should finalize the synthesis of alpha-naphthocyclinone. In pursue of this research, the racemic synthetic strategy for the key intermediate, as well as its modulation into the western and eastern fragment, has been successfully established and thus opening the path for the enantioselective totals synthesis of the target natural compounds.
该研究项目的目的是首次全合成萘环酮家族的三种天然产物α-,β-和γ-萘环酮。这三个化合物都是在1974年作为彩色色素从链霉菌的菌丝体中分离出来的,是对革兰氏阳性菌的强抗生素。通过对萘环素酮生物合成途径的深入研究,发现大自然利用吡喃萘醌单体进行二聚反应来构建萘环素酮,逆合成分析设想了一个共同的中间体,它具有完整的碳骨架和双环核心结构。该双环核心结构可以通过还原环化经由羟醛加成来构建,该方法是在Suzuki的组中开发的。环化反应的前体可以通过不对称铑催化的西部和东部片段的C-C交叉偶联反应来提供。受萘环酮生物合成的启发,这两个片段都可以从一个关键中间体吡喃萘化合物合成,考虑到合成策略,关键中间体的萘核应该通过苯甲酸酯衍生物和文献已知的手性二氢吡喃结构单元的环化来实现,该结构单元与关键中间体的立体异构中心有关。关键中间体的吡喃环可以通过内半缩醛的非对映选择性烷基化反应完全官能化。在将关键中间体调制成西部和东部片段之后,可以通过交叉偶联反应和还原环化来合成具有全碳骨架的共同中间体。在a)氧化成对萘醌部分,B)生成羧酸官能团和c)除去所有酚保护基的顺序之后,应提供目标化合物β-萘环酮。颠倒该顺序的前两个步骤的顺序(首先生成羧酸官能团,然后氧化成对萘醌部分)应允许文献已知的内酯化。再次去除所有酚保护基应导致γ-萘环酮。与生物合成类似,环氧化反应后进行光化学重排应完成α-萘环素酮的合成。在此基础上,成功地建立了关键中间体的外消旋合成策略,并将其拆分为西片段和东片段,从而为目标天然化合物的对映选择性全合成开辟了道路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dr. Mark Marcello Maturi其他文献
Dr. Mark Marcello Maturi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
胆固醇合成蛋白CYP51介导线粒体通透性转换诱发Th17/Treg细胞稳态失衡在舍格伦综合征中的作用机制研究
- 批准号:82370976
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
“肠—肝轴”PPARα/CYP8B1胆汁酸合成信号通路在减重手术改善糖脂代谢中的作用与机制
- 批准号:82370902
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
lncGEI诱导湖羊卵巢颗粒细胞E2合成的分子机制
- 批准号:32372856
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
脂肪酸合成通过GDF15/IRS2介导胰岛素抵抗促进血管内皮细胞活化导致脓毒症肺损伤的机制研究
- 批准号:82372203
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
环状RNA circ-PRKAA1调控肝癌细胞脂代谢重编程的研究
- 批准号:32000527
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
ALDH6A1缺损重塑糖脂代谢促进肝细胞癌发生的机制研究
- 批准号:91957109
- 批准年份:2019
- 资助金额:79.0 万元
- 项目类别:重大研究计划
新型滤波器综合技术-直接综合技术(Direct synthesis Technique)的研究及应用
- 批准号:61671111
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
双硅化合物反应及天然产物合成应用研究
- 批准号:21172150
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
新型M4受体选择性拮抗剂的研究
- 批准号:30973615
- 批准年份:2009
- 资助金额:32.0 万元
- 项目类别:面上项目
基于penicillide结构的类天然产物合成及其胆固醇酯转运蛋白抑制的研究
- 批准号:20872019
- 批准年份:2008
- 资助金额:32.0 万元
- 项目类别:面上项目
相似海外基金
The Influence of Developmental Exposure to Maternal Overnutrition and Metformin on Offspring Mitochondrial Health and Beta Cell Function
发育期暴露于母亲营养过剩和二甲双胍对后代线粒体健康和 β 细胞功能的影响
- 批准号:
10601500 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Application of a high throughput platform for screening directed evolution libraries
高通量平台筛选定向进化文库的应用
- 批准号:
10818241 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Regulation of Mitochondrial Metabolism by Tyr-phosphorylated ATP Synthase Alpha-Subunit and its Therapeutic Implications in Prostate Cancer
酪氨酸磷酸化 ATP 合酶 α 亚基对线粒体代谢的调节及其在前列腺癌中的治疗意义
- 批准号:
10657090 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Biochemical and Physiological Phenotypes of CV Dysfunction In Human Cell Models
人类细胞模型中CV功能障碍的生化和生理表型
- 批准号:
10714339 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Development of a high throughput platform for screening directed evolution libraries
开发用于筛选定向进化文库的高通量平台
- 批准号:
10574429 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Development of pHLIP-phosphoantigen conjugates for lymphoma therapy
开发用于淋巴瘤治疗的 pHLIP-磷酸抗原缀合物
- 批准号:
10646988 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Synthetic lethal metabolic drug combinations for castration-resistant prostate cancer
治疗去势抵抗性前列腺癌的合成致死代谢药物组合
- 批准号:
10661960 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Investigation into the Endogenous Ligand Repertoire of the Non-Classical MHC-Related Protein, MR1 in Multiple Myeloma Cell Lines
多发性骨髓瘤细胞系中非经典 MHC 相关蛋白 MR1 内源配体库的研究
- 批准号:
10557884 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Combinatorial effects of PTMs on a-Synuclein structure, function and aggregation
PTM 对 a-Synuclein 结构、功能和聚集的组合效应
- 批准号:
10391709 - 财政年份:2022
- 资助金额:
-- - 项目类别:














{{item.name}}会员




